Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00690521 · ClinicalTrials.gov registry record · NA

A Comparison of Hydrochlorothiazide and Metolazone in Combination With Furosemide in Congestive Heart Failure Patients

A NA study of Congestive Heart Failure, sponsored by University of New Mexi.

Completed
Registry status
NA
Development phase
8
Enrollment target
1
Study location

NCT00690521: Completed NA study of Congestive Heart Failure, sponsored by University of New Mexi.

NCT00690521 is a NA study of Congestive Heart Failure that has completed, run by University of New Mexi. The registered enrollment target is 8 participants, below the 330-participant average among 51 other Congestive Heart Failure trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00690521, a NA study of Congestive Heart Failure, has completed, sponsored by University of New Mexi.

COMPLETED
Registry status
NA
Development phase
8 participants
Enrollment target
1
Study location

Study Summary

Objective: To establish which combination of diuretics is the most effective in promoting diuresis in congestive heart failure patients. Secondary Objectives: To determine the duration of action of furosemide as monotherapy and in combination hydrochlorothiazide with metolazone. To determine the effect of diuretic combination therapy on neurohormonal activation. Background: Diuretic resistance occurs when a potent diuretic drug, such as furosemide, is given in therapeutic doses and fails to reduce extracellular fluid volume to the desired level in an edematous patient. Studies have shown that metolazone and hydrochlorothiazide have demonstrated a synergistic response when used in combination with furosemide in congestive heart failure patients. The current guidelines for treating diuretic resistance in congestive heart failure patients recommend the metolazone-furosemide combination. However, there is no evidence to conclude that this combination is superior to hydrochlorothiazide-furosemide in increasing diuresis. Methods: Study to compare the efficacy of hydrochlorothiazide with metolazone in combination with stable doses of furosemide in 13 patients with congestive heart failure. The primary endpoint will be change in urinary output. Secondary endpoints will be changes in weight, neurohormones (angiotensin II, catecholamines, brain natriuretic peptide, aldosterone), and electrocardiographic parameters of ventricular instability. Study procedures will be performed at the UNM General Clinical Research Center. Patients will be hospitalized for 2 separate 4-day admissions, separated by a 1-week washout period. At each admission each patient will receive furosemide in combination with either metolazone or hydrochlorothiazide (metolazone for one admission and hydrochlorothiazide for the other). Following administration of combination therapy, blood and urine samples will be collected throughout the day to chart the onset and magnitude of effect of each treatment regime

Conditions Studied

Interventions

  • DRUG Treatment of Furosemide + Hydrochlorothiazide
  • DRUG Treatment of Furosemide + Metolazone

Study Locations (1)

New Mexico

  • University Of New Mexico Hospital - Albuquerque

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2004-10-26
Est. Completion 2009-11-10
Phase NA
University of New Mexi

76 total trials

What the finished NCT00690521 record still lists

NCT00690521 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 330-participant average among 51 other Congestive Heart Failure trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Congestive Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Treatment of Furosemide + Hydrochlorothiazide is the first listed.

NCT00690521 reports a single indexed study location in New Mexico.

Frequently Asked Questions

What is clinical trial NCT00690521 about?

NCT00690521 is a clinical study titled "A Comparison of Hydrochlorothiazide and Metolazone in Combination With Furosemide in Congestive Heart Failure Patients". Objective: To establish which combination of diuretics is the most effective in promoting diuresis in congestive heart failure patients. Secondary Objectives: To determine the duration of action of furosemide as monotherapy and in combination hydrochlorothiazide with metolazone. To determine the eff...

What is the current status of trial NCT00690521?

This trial is currently completed. It is a NA study. The enrollment target is 8 participants. The study started on 2004-10-26. Estimated completion is 2009-11-10.

What conditions does trial NCT00690521 study?

This clinical trial studies the following conditions: Congestive Heart Failure.

What interventions are being tested in trial NCT00690521?

The interventions under investigation include: Treatment of Furosemide + Hydrochlorothiazide (DRUG), Treatment of Furosemide + Metolazone (DRUG).

Who is sponsoring clinical trial NCT00690521?

This trial is sponsored by University of New Mexi, which has 76 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00690521 being conducted?

This trial has 1 study location across New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Congestive Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00690521's enrollment target sits among peer trials

8 51st of 51 higher than 1 of 51 other Congestive Heart Failure trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Congestive Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00690521, the US trial registry maintained by the National Library of Medicine. NCT00690521 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.